Eyal Gottlieb

Eyal Gottlieb is a Professor at The University of Texas MD Anderson Cancer Center, where he leads research at the intersection of cancer biology and cellular metabolism. His work focuses on metabolic pathways in tumor biology, particularly mitochondrial oxidative phosphorylation and the metabolic reprogramming that drives cancer progression and immune evasion. Recent breakthroughs include identifying itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia and elucidating EGFR-driven metabolic rewiring in KRASG12D colorectal cancer. His investigations extend to kidney metabolism and therapeutic strategies for primary hyperoxaluria. His collaborations span international research networks, with findings published in Nature Communications, Blood, and EMBO Molecular Medicine.